Eli Lilly and Company (LLY) Competitors

$948.01 -26.95 (-2.76%)

Closing price 05/8/2026 03:59 PM Eastern

Extended Trading

$950.10 +2.09 (+0.22%)

As of 05/8/2026 07:59 PM Eastern

LLY vs. AMGN, BIIB, INCY, NVDA, and VKTX

Should you be buying Eli Lilly and Company stock or one of its competitors? The main competitors of Eli Lilly and Company include Amgen (AMGN), Biogen (BIIB), Incyte (INCY), NVIDIA (NVDA), and Viking Therapeutics (VKTX).

How does Eli Lilly and Company compare to Amgen?

Amgen (NASDAQ:AMGN) and Eli Lilly and Company (NYSE:LLY) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

76.5% of Amgen shares are owned by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are owned by institutional investors. 0.9% of Amgen shares are owned by company insiders. Comparatively, 0.1% of Eli Lilly and Company shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Amgen presently has a consensus price target of $357.12, indicating a potential upside of 7.66%. Eli Lilly and Company has a consensus price target of $1,218.33, indicating a potential upside of 28.51%. Given Eli Lilly and Company's stronger consensus rating and higher probable upside, analysts clearly believe Eli Lilly and Company is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	2 Sell rating(s)	14 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.48
Eli Lilly and Company	1 Sell rating(s)	4 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	2.87

Eli Lilly and Company has higher revenue and earnings than Amgen. Amgen is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$36.75B	4.87	$7.71B	$14.37	23.08
Eli Lilly and Company	$65.18B	13.70	$20.64B	$28.15	33.68

In the previous week, Eli Lilly and Company had 125 more articles in the media than Amgen. MarketBeat recorded 180 mentions for Eli Lilly and Company and 55 mentions for Amgen. Amgen's average media sentiment score of 0.95 beat Eli Lilly and Company's score of 0.92 indicating that Amgen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	32 Very Positive mention(s)	4 Positive mention(s)	12 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Eli Lilly and Company	104 Very Positive mention(s)	36 Positive mention(s)	20 Neutral mention(s)	9 Negative mention(s)	3 Very Negative mention(s)	Positive

Eli Lilly and Company has a net margin of 34.98% compared to Amgen's net margin of 20.96%. Amgen's return on equity of 137.41% beat Eli Lilly and Company's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	20.96%	137.41%	13.28%
Eli Lilly and Company	34.98%	105.77%	23.76%

Amgen has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500. Comparatively, Eli Lilly and Company has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500.

Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 3.0%. Eli Lilly and Company pays an annual dividend of $6.92 per share and has a dividend yield of 0.7%. Amgen pays out 70.1% of its earnings in the form of a dividend. Eli Lilly and Company pays out 24.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amgen has raised its dividend for 14 consecutive years and Eli Lilly and Company has raised its dividend for 11 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Eli Lilly and Company beats Amgen on 14 of the 19 factors compared between the two stocks.

How does Eli Lilly and Company compare to Biogen?

Biogen (NASDAQ:BIIB) and Eli Lilly and Company (NYSE:LLY) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

87.9% of Biogen shares are owned by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are owned by institutional investors. 0.2% of Biogen shares are owned by insiders. Comparatively, 0.1% of Eli Lilly and Company shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Biogen presently has a consensus price target of $214.23, indicating a potential upside of 10.74%. Eli Lilly and Company has a consensus price target of $1,218.33, indicating a potential upside of 28.51%. Given Eli Lilly and Company's stronger consensus rating and higher probable upside, analysts clearly believe Eli Lilly and Company is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.50
Eli Lilly and Company	1 Sell rating(s)	4 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	2.87

Eli Lilly and Company has higher revenue and earnings than Biogen. Biogen is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	2.89	$1.29B	$9.32	20.76
Eli Lilly and Company	$65.18B	13.70	$20.64B	$28.15	33.68

In the previous week, Eli Lilly and Company had 139 more articles in the media than Biogen. MarketBeat recorded 180 mentions for Eli Lilly and Company and 41 mentions for Biogen. Eli Lilly and Company's average media sentiment score of 0.92 beat Biogen's score of 0.92 indicating that Eli Lilly and Company is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	14 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eli Lilly and Company	104 Very Positive mention(s)	36 Positive mention(s)	20 Neutral mention(s)	9 Negative mention(s)	3 Very Negative mention(s)	Positive

Eli Lilly and Company has a net margin of 34.98% compared to Biogen's net margin of 13.81%. Eli Lilly and Company's return on equity of 105.77% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	13.81%	12.83%	8.01%
Eli Lilly and Company	34.98%	105.77%	23.76%

Biogen has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500. Comparatively, Eli Lilly and Company has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500.

Summary

Eli Lilly and Company beats Biogen on 15 of the 17 factors compared between the two stocks.

How does Eli Lilly and Company compare to Incyte?

Eli Lilly and Company (NYSE:LLY) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

Eli Lilly and Company presently has a consensus target price of $1,218.33, indicating a potential upside of 28.51%. Incyte has a consensus target price of $104.26, indicating a potential upside of 5.79%. Given Eli Lilly and Company's stronger consensus rating and higher probable upside, research analysts plainly believe Eli Lilly and Company is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eli Lilly and Company	1 Sell rating(s)	4 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	2.87
Incyte	1 Sell rating(s)	10 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.43

82.5% of Eli Lilly and Company shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 0.1% of Eli Lilly and Company shares are owned by company insiders. Comparatively, 17.8% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Eli Lilly and Company has a net margin of 34.98% compared to Incyte's net margin of 26.71%. Eli Lilly and Company's return on equity of 105.77% beat Incyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eli Lilly and Company	34.98%	105.77%	23.76%
Incyte	26.71%	26.66%	19.77%

Eli Lilly and Company has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. Comparatively, Incyte has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500.

Eli Lilly and Company has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eli Lilly and Company	$65.18B	13.70	$20.64B	$28.15	33.68
Incyte	$5.14B	3.83	$1.29B	$7.08	13.92

In the previous week, Eli Lilly and Company had 160 more articles in the media than Incyte. MarketBeat recorded 180 mentions for Eli Lilly and Company and 20 mentions for Incyte. Eli Lilly and Company's average media sentiment score of 0.92 beat Incyte's score of 0.70 indicating that Eli Lilly and Company is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eli Lilly and Company	104 Very Positive mention(s)	36 Positive mention(s)	20 Neutral mention(s)	9 Negative mention(s)	3 Very Negative mention(s)	Positive
Incyte	7 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Eli Lilly and Company beats Incyte on 14 of the 17 factors compared between the two stocks.

How does Eli Lilly and Company compare to NVIDIA?

Eli Lilly and Company (NYSE:LLY) and NVIDIA (NASDAQ:NVDA) are related large-cap companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

Eli Lilly and Company presently has a consensus target price of $1,218.33, indicating a potential upside of 28.51%. NVIDIA has a consensus target price of $275.25, indicating a potential upside of 27.96%. Given Eli Lilly and Company's higher probable upside, research analysts plainly believe Eli Lilly and Company is more favorable than NVIDIA.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eli Lilly and Company	1 Sell rating(s)	4 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	2.87
NVIDIA	0 Sell rating(s)	2 Hold rating(s)	48 Buy rating(s)	4 Strong Buy rating(s)	3.04

82.5% of Eli Lilly and Company shares are owned by institutional investors. Comparatively, 65.3% of NVIDIA shares are owned by institutional investors. 0.1% of Eli Lilly and Company shares are owned by company insiders. Comparatively, 4.2% of NVIDIA shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

NVIDIA has a net margin of 55.60% compared to Eli Lilly and Company's net margin of 34.98%. Eli Lilly and Company's return on equity of 105.77% beat NVIDIA's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eli Lilly and Company	34.98%	105.77%	23.76%
NVIDIA	55.60%	97.37%	70.68%

Eli Lilly and Company has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Comparatively, NVIDIA has a beta of 2.25, suggesting that its stock price is 125% more volatile than the S&P 500.

Eli Lilly and Company pays an annual dividend of $6.92 per share and has a dividend yield of 0.7%. NVIDIA pays an annual dividend of $0.04 per share and has a dividend yield of 0.0%. Eli Lilly and Company pays out 24.6% of its earnings in the form of a dividend. NVIDIA pays out 0.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Eli Lilly and Company has raised its dividend for 11 consecutive years and NVIDIA has raised its dividend for 1 consecutive years. Eli Lilly and Company is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

NVIDIA has higher revenue and earnings than Eli Lilly and Company. Eli Lilly and Company is trading at a lower price-to-earnings ratio than NVIDIA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eli Lilly and Company	$65.18B	13.70	$20.64B	$28.15	33.68
NVIDIA	$215.94B	24.21	$120.07B	$4.90	43.90

In the previous week, NVIDIA had 166 more articles in the media than Eli Lilly and Company. MarketBeat recorded 346 mentions for NVIDIA and 180 mentions for Eli Lilly and Company. Eli Lilly and Company's average media sentiment score of 0.92 beat NVIDIA's score of 0.92 indicating that Eli Lilly and Company is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eli Lilly and Company	104 Very Positive mention(s)	36 Positive mention(s)	20 Neutral mention(s)	9 Negative mention(s)	3 Very Negative mention(s)	Positive
NVIDIA	220 Very Positive mention(s)	38 Positive mention(s)	53 Neutral mention(s)	27 Negative mention(s)	7 Very Negative mention(s)	Positive

Summary

NVIDIA beats Eli Lilly and Company on 13 of the 20 factors compared between the two stocks.

How does Eli Lilly and Company compare to Viking Therapeutics?

Eli Lilly and Company (NYSE:LLY) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

Eli Lilly and Company has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eli Lilly and Company	$65.18B	13.70	$20.64B	$28.15	33.68
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A

Eli Lilly and Company has a net margin of 34.98% compared to Viking Therapeutics' net margin of 0.00%. Eli Lilly and Company's return on equity of 105.77% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eli Lilly and Company	34.98%	105.77%	23.76%
Viking Therapeutics	N/A	-71.31%	-65.35%

82.5% of Eli Lilly and Company shares are held by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are held by institutional investors. 0.1% of Eli Lilly and Company shares are held by insiders. Comparatively, 5.3% of Viking Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Eli Lilly and Company has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500.

In the previous week, Eli Lilly and Company had 168 more articles in the media than Viking Therapeutics. MarketBeat recorded 180 mentions for Eli Lilly and Company and 12 mentions for Viking Therapeutics. Eli Lilly and Company's average media sentiment score of 0.92 beat Viking Therapeutics' score of 0.14 indicating that Eli Lilly and Company is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eli Lilly and Company	104 Very Positive mention(s)	36 Positive mention(s)	20 Neutral mention(s)	9 Negative mention(s)	3 Very Negative mention(s)	Positive
Viking Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Eli Lilly and Company currently has a consensus target price of $1,218.33, indicating a potential upside of 28.51%. Viking Therapeutics has a consensus target price of $95.50, indicating a potential upside of 204.82%. Given Viking Therapeutics' higher probable upside, analysts clearly believe Viking Therapeutics is more favorable than Eli Lilly and Company.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eli Lilly and Company	1 Sell rating(s)	4 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	2.87
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.85

Summary

Eli Lilly and Company beats Viking Therapeutics on 12 of the 16 factors compared between the two stocks.

Get Eli Lilly and Company News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LLY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LLY vs. The Competition

Export

Metric	Eli Lilly and Company	Large Cap Pharma Industry	Medical Sector	NYSE Exchange
Market Cap	$918.16B	$290.40B	$6.25B	$22.98B
Dividend Yield	0.71%	2.81%	2.78%	4.01%
P/E Ratio	33.68	25.69	20.64	28.60
Price / Sales	13.70	4.79	534.02	110.85
Price / Cash	38.78	12.43	43.29	25.08
Price / Book	28.61	6.75	9.98	4.62
Net Income	$20.64B	$11.61B	$3.54B	$1.07B
7 Day Performance	-1.78%	-1.39%	3.50%	0.46%
1 Month Performance	-0.89%	-2.95%	4.17%	4.09%
1 Year Performance	28.77%	22.77%	41.85%	28.48%

Eli Lilly and Company Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LLY Eli Lilly and Company	4.9056 of 5 stars	$948.01 -2.8%	$1,218.33 +28.5%	N/A	$918.16B	$65.18B	33.68	50,000	Trending News Dividend Announcement Analyst Forecast Analyst Revision
AMGN Amgen	4.3442 of 5 stars	$329.82 -4.7%	$357.54 +8.4%	N/A	$178.00B	$36.75B	22.95	31,500	Analyst Forecast Insider Trade Analyst Revision
BIIB Biogen	3.8122 of 5 stars	$187.06 -1.2%	$214.23 +14.5%	N/A	$27.62B	$9.89B	20.07	7,500	Trending News Analyst Revision
INCY Incyte	4.1514 of 5 stars	$96.91 +1.7%	$104.26 +7.6%	N/A	$19.36B	$5.14B	13.69	2,844
NVDA NVIDIA	4.9673 of 5 stars	$198.45 -0.6%	$275.25 +38.7%	N/A	$4.82T	$215.94B	40.50	42,000	Trending News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:LLY) was last updated on 5/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eli Lilly and Company (LLY) Competitors

LLY vs. AMGN, BIIB, INCY, NVDA, and VKTX

How does Eli Lilly and Company compare to Amgen?

Summary

How does Eli Lilly and Company compare to Biogen?

Summary

How does Eli Lilly and Company compare to Incyte?

Summary

How does Eli Lilly and Company compare to NVIDIA?

Summary

How does Eli Lilly and Company compare to Viking Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LLY vs. The Competition

Eli Lilly and Company Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eli Lilly and Company (LLY) Competitors

LLY vs. AMGN, BIIB, INCY, NVDA, and VKTX

How does Eli Lilly and Company compare to Amgen?

Do institutionals and insiders believe in AMGN or LLY?

Do analysts prefer AMGN or LLY?

Which has better earnings and valuation, AMGN or LLY?

Does the media favor AMGN or LLY?

Is AMGN or LLY more profitable?

Which has more risk and volatility, AMGN or LLY?

Is AMGN or LLY a better dividend stock?

Summary

How does Eli Lilly and Company compare to Biogen?

Do institutionals & insiders have more ownership in BIIB or LLY?

Do analysts prefer BIIB or LLY?

Which has higher earnings & valuation, BIIB or LLY?

Does the media prefer BIIB or LLY?

Is BIIB or LLY more profitable?

Which has more risk & volatility, BIIB or LLY?

Summary

How does Eli Lilly and Company compare to Incyte?

Do analysts recommend LLY or INCY?

Do institutionals & insiders believe in LLY or INCY?

Is LLY or INCY more profitable?

Which has more risk and volatility, LLY or INCY?

Which has better earnings & valuation, LLY or INCY?

Does the media favor LLY or INCY?

Summary

How does Eli Lilly and Company compare to NVIDIA?

Do analysts recommend LLY or NVDA?

Do institutionals and insiders believe in LLY or NVDA?

Is LLY or NVDA more profitable?

Which has more volatility and risk, LLY or NVDA?

Is LLY or NVDA a better dividend stock?

Which has higher valuation and earnings, LLY or NVDA?

Does the media favor LLY or NVDA?

Summary

How does Eli Lilly and Company compare to Viking Therapeutics?

Which has stronger earnings & valuation, LLY or VKTX?

Is LLY or VKTX more profitable?

Do insiders and institutionals believe in LLY or VKTX?

Which has more risk and volatility, LLY or VKTX?

Does the media refer more to LLY or VKTX?

Do analysts prefer LLY or VKTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LLY vs. The Competition

Eli Lilly and Company Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools